Core Viewpoint - HCM's stock rose over 6% to $15.76 following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Conferences - HCM will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Key Research Studies - The latest analysis results of the SACHI and SAVANNAH studies, which evaluate the efficacy of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel selective and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO meeting [1]
和黄医药(HCM.US)涨逾6% 将公布自研化合物数项研究最新数据